The 1984 Drug Price Competition and Patent Term Restoration Act (the Waxman-Hatch Act) is unique in many ways. This Law was the first change in U.S. patent terms since 1861. It simultaneously lowered the barrier to entry for generic drug firms and increased patent terms for new drugs delayed by...

Recently, the Federal Trade Commission (FTC) has accused breakfast cereal manufacturers of illegal monopolization (1971).A major basis for the charge is the FTC belief that high advertising expenditures by the companies create effective entry barriers. One FTC study (1969) reached this...

In September 2015, the first biosimilar drug, Zarxio, was launched on the U.S. market. While the impact of generic entry on the small molecule branded market in the U.S. is well-understood, the impact of biosimilar entry on the large molecule biologic market has only been studied in Europe and...